| Income statement (USD) | Q2 2026 ended Jun 28, 2026 | Q1 2026 ended Mar 29, 2026 | Q4 2025 ended Dec 28, 2025 | Q3 2025 ended Sep 28, 2025 | Q2 2025 ended Jun 29, 2025 | Q1 2025 ended Mar 30, 2025 | Q4 2024 ended Dec 29, 2024 | Q3 2024 ended Sep 29, 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 25.31B | 24.06B | 24.56B | 23.99B | 23.74B | 21.89B | 22.52B | 22.47B |
| Cost of revenue | 8.05B | 8.11B | 7.97B | 7.30B | 7.63B | 7.36B | 7.13B | 6.96B |
| Gross profit | 17.26B | 15.96B | 16.60B | 16.69B | 16.11B | 14.54B | 15.39B | 15.51B |
| Research and development | 3.65B | 3.53B | -10.30B | 3.67B | 3.52B | 3.23B | -10.09B | 4.95B |
| Selling, general and admin | 6.43B | 6.03B | 6.75B | 5.92B | 5.89B | 5.11B | 6.45B | 5.48B |
| Interest expense | 281.00M | 272.00M | 214.00M | 245.00M | 308.00M | 204.00M | 137.00M | 193.00M |
| Income before tax | 6.75B | 5.99B | 4.97B | 7.49B | 6.49B | 13.63B | 3.89B | 3.34B |
| Income tax | 1.21B | 755.00M | -150.00M | 2.34B | 954.00M | 2.63B | 456.00M | 644.00M |
| Net income | 5.53B | 5.24B | 5.12B | 5.15B | 5.54B | 11.00B | 3.43B | 2.69B |
| EPS | 2.30 | 2.17 | 2.12 | 2.14 | 2.30 | 4.57 | 1.42 | 1.12 |
| EPS (diluted) | 2.27 | 2.14 | 2.09 | 2.12 | 2.29 | 4.54 | 1.41 | 1.11 |
| Diluted shares | 2.44B | 2.45B | 4.60M | 2.43B | 2.42B | 2.42B | -100.0K | 2.43B |
| Dividends per share | 1.34 | 1.30 | 1.30 | 1.30 | 1.30 | 1.24 | 1.24 | 1.24 |
From Johnson & Johnson's 10-K and 10-Q filings with the SEC. Fourth quarters, and quarters where the company only reported year-to-date totals, are worked out by subtracting the earlier quarters. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read income statement or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.